Autolus Therapeutics is well capitalized and ready to drive the launch and commercialization of its product, obe-cel.
5 reports, 3 independent
Updated Sep 12
Gone quiet
- Reports
- 5
- Developments
- 3
- Repetition
- 40%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Autolus Therapeutics is well capitalized and ready to drive the launch and commercialization of its product, obe-cel.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Autolus secured credit facility funding and reported revenue growth driven by AUCATZYL.1 source
CEO provides updates on commercial launch and product sales drive revenue growth.1 source
Autolus Therapeutics is well capitalized to drive the launch and commercialization of obe-cel.1 source
Keep exploring
The entities involved
-
Autolus Therapeutics
company in London, United Kingdom
Nothing else this week.
Coverage
Newest first; wire copies grouped- insidermonkey.com
- yahoo.com
- TipRanksAutolus Therapeutics sees cash runway to launch, commercialization of obe-cel Cash, cash equivalents and marketable securities at June 30, 2025, totalled $454.3 million, as compared to $588.0 million
- Unknown outlet